Electric Therapy Traction Table Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
The global Remicade (Infliximab) Monoclonal Antibody market was valued at US$ 2623.8 million in 2022 and is projected to reach US$ 3781.3 million by 2029, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
This report aims to provide a comprehensive presentation of the global market for Remicade (Infliximab) Monoclonal Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (Infliximab) Monoclonal Antibody. This report contains market size and forecasts of Remicade (Infliximab) Monoclonal Antibody in global, including the following market information:
Global Remicade (Infliximab) Monoclonal Antibody Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Remicade (Infliximab) Monoclonal Antibody Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Remicade (Infliximab) Monoclonal Antibody companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Remicade (Infliximab) Monoclonal Antibody manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Remicade (Infliximab) Monoclonal Antibody Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Remicade (Infliximab) Monoclonal Antibody Market Segment Percentages, by Type, 2022 (%)
Brand
Biosimilar
Global Remicade (Infliximab) Monoclonal Antibody Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Remicade (Infliximab) Monoclonal Antibody Market Segment Percentages, by Application, 2022 (%)
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Global Remicade (Infliximab) Monoclonal Antibody Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Remicade (Infliximab) Monoclonal Antibody Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Remicade (Infliximab) Monoclonal Antibody revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Remicade (Infliximab) Monoclonal Antibody revenues share in global market, 2022 (%)
Key companies Remicade (Infliximab) Monoclonal Antibody sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Remicade (Infliximab) Monoclonal Antibody sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
J & J
Pfizer
Organon
Amgen
Outline of Major Chapters:
Chapter 1: Introduces the definition of Remicade (Infliximab) Monoclonal Antibody, market overview.
Chapter 2: Global Remicade (Infliximab) Monoclonal Antibody market size in revenue and volume.
Chapter 3: Detailed analysis of Remicade (Infliximab) Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Remicade (Infliximab) Monoclonal Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Remicade (Infliximab) Monoclonal Antibody capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Remicade (Infliximab) Monoclonal Antibody Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Remicade (Infliximab) Monoclonal Antibody Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Remicade (Infliximab) Monoclonal Antibody Overall Market Size
2.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size: 2022 VS 2029
2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales: 2018-2029
3 Company Landscape
3.1 Top Remicade (Infliximab) Monoclonal Antibody Players in Global Market
3.2 Top Global Remicade (Infliximab) Monoclonal Antibody Companies Ranked by Revenue
3.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Companies
3.4 Global Remicade (Infliximab) Monoclonal Antibody Sales by Companies
3.5 Global Remicade (Infliximab) Monoclonal Antibody Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Remicade (Infliximab) Monoclonal Antibody Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Remicade (Infliximab) Monoclonal Antibody Product Type
3.8 Tier 1, Tier 2 and Tier 3 Remicade (Infliximab) Monoclonal Antibody Players in Global Market
3.8.1 List of Global Tier 1 Remicade (Infliximab) Monoclonal Antibody Companies
3.8.2 List of Global Tier 2 and Tier 3 Remicade (Infliximab) Monoclonal Antibody Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Remicade (Infliximab) Monoclonal Antibody Market Size Markets, 2022 & 2029
4.1.2 Brand
4.1.3 Biosimilar
4.2 By Type - Global Remicade (Infliximab) Monoclonal Antibody Revenue & Forecasts
4.2.1 By Type - Global Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2023
4.2.2 By Type - Global Remicade (Infliximab) Monoclonal Antibody Revenue, 2024-2029
4.2.3 By Type - Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share, 2018-2029
4.3 By Type - Global Remicade (Infliximab) Monoclonal Antibody Sales & Forecasts
4.3.1 By Type - Global Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2023
4.3.2 By Type - Global Remicade (Infliximab) Monoclonal Antibody Sales, 2024-2029
4.3.3 By Type - Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share, 2018-2029
4.4 By Type - Global Remicade (Infliximab) Monoclonal Antibody Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Remicade (Infliximab) Monoclonal Antibody Market Size, 2022 & 2029
5.1.2 Ankylosing Spondylitis
5.1.3 Rheumatoid Arthritis
5.1.4 Crohn’s Disease
5.1.5 Other
5.2 By Application - Global Remicade (Infliximab) Monoclonal Antibody Revenue & Forecasts
5.2.1 By Application - Global Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2023
5.2.2 By Application - Global Remicade (Infliximab) Monoclonal Antibody Revenue, 2024-2029
5.2.3 By Application - Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share, 2018-2029
5.3 By Application - Global Remicade (Infliximab) Monoclonal Antibody Sales & Forecasts
5.3.1 By Application - Global Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2023
5.3.2 By Application - Global Remicade (Infliximab) Monoclonal Antibody Sales, 2024-2029
5.3.3 By Application - Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share, 2018-2029
5.4 By Application - Global Remicade (Infliximab) Monoclonal Antibody Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Remicade (Infliximab) Monoclonal Antibody Market Size, 2022 & 2029
6.2 By Region - Global Remicade (Infliximab) Monoclonal Antibody Revenue & Forecasts
6.2.1 By Region - Global Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2023
6.2.2 By Region - Global Remicade (Infliximab) Monoclonal Antibody Revenue, 2024-2029
6.2.3 By Region - Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share, 2018-2029
6.3 By Region - Global Remicade (Infliximab) Monoclonal Antibody Sales & Forecasts
6.3.1 By Region - Global Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2023
6.3.2 By Region - Global Remicade (Infliximab) Monoclonal Antibody Sales, 2024-2029
6.3.3 By Region - Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2029
6.4.2 By Country - North America Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2029
6.4.3 US Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.4.4 Canada Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.4.5 Mexico Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2029
6.5.2 By Country - Europe Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2029
6.5.3 Germany Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5.4 France Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5.5 U.K. Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5.6 Italy Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5.7 Russia Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5.8 Nordic Countries Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.5.9 Benelux Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2029
6.6.2 By Region - Asia Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2029
6.6.3 China Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.6.4 Japan Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.6.5 South Korea Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.6.6 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.6.7 India Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2029
6.7.2 By Country - South America Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2029
6.7.3 Brazil Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.7.4 Argentina Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales, 2018-2029
6.8.3 Turkey Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.8.4 Israel Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.8.5 Saudi Arabia Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
6.8.6 UAE Remicade (Infliximab) Monoclonal Antibody Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 J & J
7.1.1 J & J Company Summary
7.1.2 J & J Business Overview
7.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Major Product Offerings
7.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Sales and Revenue in Global (2018-2023)
7.1.5 J & J Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Major Product Offerings
7.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Organon
7.3.1 Organon Company Summary
7.3.2 Organon Business Overview
7.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Major Product Offerings
7.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Sales and Revenue in Global (2018-2023)
7.3.5 Organon Key News & Latest Developments
7.4 Amgen
7.4.1 Amgen Company Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Major Product Offerings
7.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Sales and Revenue in Global (2018-2023)
7.4.5 Amgen Key News & Latest Developments
8 Global Remicade (Infliximab) Monoclonal Antibody Production Capacity, Analysis
8.1 Global Remicade (Infliximab) Monoclonal Antibody Production Capacity, 2018-2029
8.2 Remicade (Infliximab) Monoclonal Antibody Production Capacity of Key Manufacturers in Global Market
8.3 Global Remicade (Infliximab) Monoclonal Antibody Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Remicade (Infliximab) Monoclonal Antibody Supply Chain Analysis
10.1 Remicade (Infliximab) Monoclonal Antibody Industry Value Chain
10.2 Remicade (Infliximab) Monoclonal Antibody Upstream Market
10.3 Remicade (Infliximab) Monoclonal Antibody Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Remicade (Infliximab) Monoclonal Antibody Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LED Light-Up Blanket Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 116 |
Pelvic Floor Functional Magnetic Stimulator Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Multi-Modality Biofeedback System Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
High Frequency Evaluation and Therapy Device Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Choose License Type
Why Choose Us ?
24/7 Research support
Quality assurance
Information security
The report efficiently evaluates the market from various dimensions to deliver an
end-product that is informative, elaborate, and accurate and includes detailed
market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast.
The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of
xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the
industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market
opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE
analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing
initiatives, pricing analysis, competitive landscape which help businesses in
decision making. The analysis data is based on current and historical market trends
which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any
organization to gain insight into specific business sector, aligned with specific area
of interest. Thus, SMI offers more accurate, pragmatic, and actionable information
specifically tailored to suit your business needs.
